newsfilter
← Latest News
GlobeNewswire·

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline